

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Bernard R. Brodeur et al.
Application No. : 09/684,883
Filed : October 6, 2000
For : PROTEINASE K RESISTANT SURFACE PROTEIN OF
NEISSERIA MENINGITIDIS

Examiner: : Albert Mark Navarro
Art Unit : 1645
Docket No. : 484112.417C1
Date : April 10, 2007

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. Copies of cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of any other cited references are enclosed. With respect to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the U.S. Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of that is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed; however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Mae Joanne Rosok
Registration No. 48,903

MJR:lw

Enclosures:
Information Disclosure Statement
Cited References (9)

701 Fifth Avenue, Suite 5400
Seattle, Washington 98104
Phone: (206) 622-4900
Fax: (206) 682-6031

936468_1.DOC



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**FOURTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

ATTY. DOCKET NO.
484112.417C1

APPLICATION NO.
09/684,883

APPLICANTS
Bernard R. Brodeur

FILING DATE
October 6, 2000

GROUP ART UNIT
1645

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|----|-----------------|---------|------|-------|----------|-------------------------------|
| | AA | 5,106,726 | 4/21/92 | Wang | 435 | 5 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION | |
|--|----|--------------------|------|---------|-------------|----|
| | | | | | YES | NO |
| | AB | | | | | |
| | AC | | | | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|--|
| | AD | Cannon et al., "Monoclonal Antibody that Recognizes an Outer Membrane Antigen Common to the Pathogenic <i>Neisseria</i> Species but not to Most Nonpathogenic <i>Neissera</i> Species," <i>Infection and Immunity</i> 43(3):994-999, March 1984. |
| | AE | Costa et al., "Meningococcal Disease in São Paulo, Brazil," <i>NIPH Annals</i> 14(2):215-218, December 1991. |
| | AF | Frasch et al., "Development and Evaluation of Group B Serotype 2 Protein Vaccines: Report of a Group B Field Trial," <i>Medecine Tropicale</i> 43(2):177-180 (1983). |
| | AG | Goldschneider et al., "Human Immunity to the Meningococcus: The Role of Humoral Antibodies," <i>Journal of Experimental Medicine</i> 129:1307-1326, 1969. |
| | AH | Goldschneider et al., "Human Immunity to the Meningococcus: Development of Natural Immunity," <i>Journal of Experimental Medicine</i> 129:1327-1348, 1969. |
| | AI | Sierra et al., "Vaccine Against Group B <i>Neisseria</i> Meningitidis: Protection Trial and Mass Vaccination Results in Cuba," <i>NIPH Annals</i> 14(2):195-210, December 1991. |
| | AJ | Wang et al., "Development of a <i>Neisseria meningitidis</i> Group B Serotype 2b Protein Vaccine and Evaluation in a Mouse Model," <i>Infection and Immunity</i> 46(2):408-414, November 1984. |
| | AK | Wedge et al., "Human Immunoglobulin G Subclass Immune Response to Outer Membrane Antigens in Meningococcal Group B Vaccine," <i>Journal of Clinical Microbiology</i> 25(8):1349-1353, August 1987. |
| | AL | Zollinger et al., "Meningococcal Serogroup B Vaccine Protection Trial and Follow-up Studies in Chile," <i>NIPH Annals</i> 14(2):211-213, December 1991. |
| | AM | |
| | AN | |
| | AO | |

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).